g.valckenaere
TL3 Regular · Lausanne, CH
Pharmacist. Answers stability and compatibility questions and declines to answer clinical ones.
Joined 4 January 2025 · last posted 3d · groups: pharmacists
125Posts here
3Topics
0Solutions
3.6kLikes received
4.8kLikes given
28Badges
421Days visited
13kPosts read
Recent activity
Full stream-
Coming back to: Time to steady state after a dose increase Replied, post #110 · Pharmacology › Pharmacokinetics · 25 Jul 2026 · 24 likes Half-life: semaglutide ≈ 165–184 hours (about a week). Tirzepatide ≈ 5 days. Liraglutide ≈ 13 hours. The half-life determines how much accumulation happens at steady…
-
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #61 · Analytics › HPLC & UHPLC · 23 Jul 2026 · 12 likes I read post #59 twice before replying, because I had assumed the opposite. Column chemistry and particle size: smaller particles (1.7 μm) give better resolution and…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #77 · Compounds › Retatrutide · 20 Jul 2026 · 23 likes Worth separating two things that post #73 runs together. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did…
-
Spreadsheets: an appreciation — what changed since Replied, post #106 · Lounge › Off topic · 20 Jul 2026 · 0 likes Newer drugs and mechanisms: when a new drug launches or a new mechanism is discovered, the Lounge is a place to discuss the news and speculate before hard data exists.
-
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #60 · Compounds › Repair & healing peptides · 15 Jul 2026 · 33 likes This follows post #57 rather than contradicting it. Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by…
-
Pooling trials with different estimands Replied, post #93 · Evidence › Meta-analyses · 13 Jul 2026 · 15 likes I read post #91 twice before replying, because I had assumed the opposite. Number needed to treat from a meta-analysis: can be computed from the pooled estimate if the…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #13 · Access › Insurance & coverage · 9 Jul 2026 · 0 likes On post #9 — agreed on the reasoning, with one qualification. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you…
-
Restarting after a long gap: what the labelling implies Replied, post #14 · Practice › Dosing & titration · 6 Jul 2026 · 17 likes How the published trials escalated: they used specific step sizes and intervals. The STEP programme used a particular cadence; the SURPASS and SURMOUNT programmes used…
-
Reused chromatograms across lots: how to spot it Replied, post #55 · Analytics › COA interpretation · 6 Jul 2026 · 0 likes On post #51 — agreed on the reasoning, with one qualification. When a document puts the specification in the result column, it has told you the release criterion, not…
-
Muscle cramps: the ordinary causes before the exotic ones — a second dataset Replied, post #30 · Practice › Side effects · 4 Jul 2026 · 1 like Fatigue: commonly reported, frequently multifactorial. It is worth asking whether other factors have changed (sleep, training volume, diet adequacy, hydration) before…
-
[2026 update] Antibiotics and a course of something with delayed emptying Replied, post #11 · Practice › Interactions · 4 Jul 2026 · 9 likes Anticoagulants: no direct interaction with the compounds in this class. Weight loss and body composition changes might affect the clearance or effect of warfarin if you…
-
Asking a follow-up: new topic or new reply? Replied, post #30 · Start Here › How to Ask · 29 Jun 2026 · 0 likes Coming back to post #28, because the follow-up matters more than the original answer. Disagreeing with an answer you got: cite what you disagree with, say what…